摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(9-Hydroxy-4-methoxy-1-oxo-2,3-dihydro-1H-phenalen-2-yl)-acetamide | 179041-68-0

中文名称
——
中文别名
——
英文名称
N-(9-Hydroxy-4-methoxy-1-oxo-2,3-dihydro-1H-phenalen-2-yl)-acetamide
英文别名
N-(1-oxo-9-hydroxy-4-methoxy-2,3-dihydro-1H-phenalen-2-yl)acetamide;N-(4-hydroxy-9-methoxy-3-oxo-1,2-dihydrophenalen-2-yl)acetamide
N-(9-Hydroxy-4-methoxy-1-oxo-2,3-dihydro-1H-phenalen-2-yl)-acetamide化学式
CAS
179041-68-0
化学式
C16H15NO4
mdl
——
分子量
285.299
InChiKey
QSGJAWCSMSGFBG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    75.6
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-(9-Hydroxy-4-methoxy-1-oxo-2,3-dihydro-1H-phenalen-2-yl)-acetamide 在 palladium on activated charcoal 氢气溶剂黄146 作用下, 反应 28.0h, 以37%的产率得到N-(4-Hydroxy-9-methoxy-2,3-dihydro-1H-phenalen-2-yl)-acetamide
    参考文献:
    名称:
    Synthesis of 2-Amido-2,3-dihydro-1H-phenalene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors
    摘要:
    Tetrahydroanthracene, tetrahydrophenanthrene, and tetrahydrophenalene moieties were used to design novel constrained melatoninergic agents. Compounds 1 and 2 were synthesized from the cyclization of the aryl succinic acids 6a,b followed by catalytic reduction, Curtius degradation to the amino derivatives, and acetylation. The phenalene derivatives 3 were prepared by cyclization of the aza lactones of the corresponding alpha-N-acetyl amino acids. The ketone derivatives were reduced directly by catalytic hydrogenation to produce the compounds 3. The different compounds were evaluated in vitro in binding assays using 2-[I-125]iodomelatonin and chicken brain membranes. Melatonin and 2-acetamido-8-methoxytetralin were used as the reference compounds. The results showed the superiority of the dihydrophenalene framework 3 over tho se of tetrahydro anthracene and tetrahydrophenanthrene. 3a had relatively good affinity for melatonin receptors (K-i = 28.7 nM). Introduction of an additional methoxy group gave a derivative (3c) with nanomolar affinity (K-i = 0.7 nM), confirming the existence of a secondary binding site in the receptor which has been described previously. An increase in the affinity was also observed with the propionamido derivative 3e (K-i = 6.0 nM). The potential agonist properties of the compound 3e were evaluated on the dermal melanocytes of Xenopus laevis tadpoles. At the concentration of 2.3 nM (5 x K-i), melatonin gave melanophore index value of 1. Similarly to melatonin, 3e was shown to be a potent agonist of the melanosome aggregation.
    DOI:
    10.1021/jm960219h
  • 作为产物:
    描述:
    (2,7-dimethoxynaphth-1-yl)methanol 在 吡啶sodium hydroxide三氯化铝氯化亚砜 、 sodium hydride 、 溶剂黄146 作用下, 以 乙醇甲苯 为溶剂, 反应 28.67h, 生成 N-(9-Hydroxy-4-methoxy-1-oxo-2,3-dihydro-1H-phenalen-2-yl)-acetamide
    参考文献:
    名称:
    Synthesis of 2-Amido-2,3-dihydro-1H-phenalene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors
    摘要:
    Tetrahydroanthracene, tetrahydrophenanthrene, and tetrahydrophenalene moieties were used to design novel constrained melatoninergic agents. Compounds 1 and 2 were synthesized from the cyclization of the aryl succinic acids 6a,b followed by catalytic reduction, Curtius degradation to the amino derivatives, and acetylation. The phenalene derivatives 3 were prepared by cyclization of the aza lactones of the corresponding alpha-N-acetyl amino acids. The ketone derivatives were reduced directly by catalytic hydrogenation to produce the compounds 3. The different compounds were evaluated in vitro in binding assays using 2-[I-125]iodomelatonin and chicken brain membranes. Melatonin and 2-acetamido-8-methoxytetralin were used as the reference compounds. The results showed the superiority of the dihydrophenalene framework 3 over tho se of tetrahydro anthracene and tetrahydrophenanthrene. 3a had relatively good affinity for melatonin receptors (K-i = 28.7 nM). Introduction of an additional methoxy group gave a derivative (3c) with nanomolar affinity (K-i = 0.7 nM), confirming the existence of a secondary binding site in the receptor which has been described previously. An increase in the affinity was also observed with the propionamido derivative 3e (K-i = 6.0 nM). The potential agonist properties of the compound 3e were evaluated on the dermal melanocytes of Xenopus laevis tadpoles. At the concentration of 2.3 nM (5 x K-i), melatonin gave melanophore index value of 1. Similarly to melatonin, 3e was shown to be a potent agonist of the melanosome aggregation.
    DOI:
    10.1021/jm960219h
点击查看最新优质反应信息

文献信息

  • Tricyclic amides
    申请人:Adir et Compagnie
    公开号:US05712312A1
    公开(公告)日:1998-01-27
    The invention relates to a compound selected from these of formula (I): ##STR1## in which R.sub.7, R.sub.8, Y, n and A are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.
    本发明涉及选择自以下公式(I)中的化合物:##STR1## 其中R.sub.7,R.sub.8,Y,n和A如描述中所定义,并且含有相同的药物产品,用于治疗褪黑素系统的疾病。
  • Amides tricycliques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
    申请人:ADIR ET COMPAGNIE
    公开号:EP0737670A1
    公开(公告)日:1996-10-16
    L'invention concerne les composés de formule (I) : dans laquelle R7, R8, Y, n et A sont tels que définis dans la description. Médicaments.
    本发明涉及式 (I) 化合物: 其中 R7、R8、Y、n 和 A 如说明书中所定义。 药物。
  • US5712312A
    申请人:——
    公开号:US5712312A
    公开(公告)日:1998-01-27
  • US5849781A
    申请人:——
    公开号:US5849781A
    公开(公告)日:1998-12-15
  • Synthesis of 2-Amido-2,3-dihydro-1<i>H</i>-phenalene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors
    作者:Monique Mathé-Allainmat、Florence Gaudy、Sames Sicsic、Anne-Laure Dangy-Caye、Shuren Shen、Béatrice Brémont、Zohra Benatalah、Michel Langlois、Pierre Renard、Philippe Delagrange
    DOI:10.1021/jm960219h
    日期:1996.1.1
    Tetrahydroanthracene, tetrahydrophenanthrene, and tetrahydrophenalene moieties were used to design novel constrained melatoninergic agents. Compounds 1 and 2 were synthesized from the cyclization of the aryl succinic acids 6a,b followed by catalytic reduction, Curtius degradation to the amino derivatives, and acetylation. The phenalene derivatives 3 were prepared by cyclization of the aza lactones of the corresponding alpha-N-acetyl amino acids. The ketone derivatives were reduced directly by catalytic hydrogenation to produce the compounds 3. The different compounds were evaluated in vitro in binding assays using 2-[I-125]iodomelatonin and chicken brain membranes. Melatonin and 2-acetamido-8-methoxytetralin were used as the reference compounds. The results showed the superiority of the dihydrophenalene framework 3 over tho se of tetrahydro anthracene and tetrahydrophenanthrene. 3a had relatively good affinity for melatonin receptors (K-i = 28.7 nM). Introduction of an additional methoxy group gave a derivative (3c) with nanomolar affinity (K-i = 0.7 nM), confirming the existence of a secondary binding site in the receptor which has been described previously. An increase in the affinity was also observed with the propionamido derivative 3e (K-i = 6.0 nM). The potential agonist properties of the compound 3e were evaluated on the dermal melanocytes of Xenopus laevis tadpoles. At the concentration of 2.3 nM (5 x K-i), melatonin gave melanophore index value of 1. Similarly to melatonin, 3e was shown to be a potent agonist of the melanosome aggregation.
查看更多

同类化合物

迫萘合環己-1,3-二酮 赫金青霉素 萘嵌苯酮 富拉烯酮 9-羟基-萘嵌苯-1-酮 9-甲基氨基-萘嵌苯-1-酮 9-巯基-萘嵌苯-1-酮 9-去甲基FR-901235 9-二甲基氨基-1H-萘嵌苯-1-酮 9-丁氧基-1H-萘嵌苯-1-酮 6b,7a-二氢-7H-环丙并[a]苊烯-7-胺盐酸盐(1:1) 6-羟基-3-甲基-1H-萘嵌苯-1-酮 6-羟基-1H-萘嵌苯-1-酮 6-溴-1H-萉 6-氨基-1-萉酮 3-羟基-1H-PHENALEN-1-酮 2-甲氧基非那烯酮 2-甲基-1-氧代-1H-非那烯-3-乙酸 2-氯-6-(3-羟基丙基)氨基-1H-萉-1-酮 2,3-二氢-6-甲氧基萘嵌苯-1-酮 2,3-二氢-1H-萉 2,3-二氢-1H-苯并-1-酮 1H-非那烯并[2,1-d][1,3]噻唑 1H-非那烯 1H-萘嵌苯-1-酮腙 1-硫酮-9-甲基氨基-非那烯 (R)-8,9-二氢-4,5,6,7-四羟基-1,8,8,9-四甲基-3H-非那烯并(1,2-b)呋喃-3-酮 2-hydroxy-2-piperidino-phenalene-1,3-dione 9-[(4-pyrimidin-2-yl)piperazin-1-yl]-1H-phenalen-1-one N-[2-(4,9-dimethoxy-2,3-dihydro-1H-1-phenalenyl)ethyl]butanamide N-[2-(9-methoxy-2,3-dihydro-1H-1-phenalenyl)ethyl]butanamide 9-methyl-9-(2-methylpropenyl)-8,9-dihydrophenaleno[1,2-b]furan-7-one 3-((cyclohexylmethyl)amino)-6-(cyclohexylthio)-1-oxo-1H-phenalene-2-carbonitrile 9-(4-benzylpiperazin-1-yl)-1H-phenalen-1-one perchlorophenalenyl radical 6-((4-bromophenyl)thio)-1-oxo-1H-phenalene-2,3-dicarbonitrile methyl 3-((6-((4-bromophenyl)thio)-2-cyano-1-oxo-1H-phenalen-3-yl)amino)propanoate 3-((6-((4-bromophenyl)thio)-2-cyano-1-oxo-1H-phenalen-3-yl)amino)propanoic acid 3-((6-((4-bromophenyl)thio)-2-cyano-1-oxo-1H-phenalen-3-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)propanamide 1,1-dimethyl-1a,11b-dihydro-1H-benzo[k]cyclopropa[4,5]cyclopent[1,2,3-cd]fluoranthene 6-(cyclopentylthio)-1-oxo-1H-phenalene-2,3-dicarbonitrile 5-propyl-9-hydroxyphenalenone N-[2-(4,9-dimethoxy-2,3-dihydro-1H-1-phenalenyl)ethyl]propanamide N-[2-(4-methoxy-2,3-dihydro-1H-1-phenalenyl)ethyl]propanamide N-benzyl-1,2,3,10-tetrahydronaphtho[1,8-fg]indol-7-yl trifluoromethanesulfonate N-benzyl-7-ethyl-1,2,3,10-tetrahydronaphtho[1,8-fg]indole 1-oxo-1H-phenalene-2,3-dicarbonitrile 1-((1-oxo-1H-phenalen-2-yl)methyl)pyridinium chloride 9-[(2-hydroxyethyl)(methyl)amino]-1H-phenalen-1-one 6-phenylsulfanyl-2,3-dicyanophenalenone